Activity of Two Interleukins Perpetuate Chronic Autoimmune Conditions
By LabMedica International staff writers Posted on 25 Jan 2017 |
Image: Molecular structural model of interleukin 15 (IL-15) (Photo courtesy of Wikimedia Commons).
A mouse model of "dry eye disease" was used to demonstrate the link between interleukins 7 and 15 and the pathogenic memory Th17 cells that mediate the autoimmune disease.
Th17 (T helper 17) cells are principal mediators of many autoimmune conditions. Persistent memory Th17 cells have been revealed as crucial in mediating the chronicity of various autoimmune disorders; however, the underlying mechanisms maintaining memory Th17 cells have remained elusive.
Investigators at Harvard Medical School used a mouse model of an ocular autoimmune disease to further elucidate the mechanism controlling the behavior of Th17 cells,
The investigators reported in the November 26, 2016, online edition of the Journal of Autoimmunity that both IL-7 and IL-15 were critical for maintaining pathogenic memory Th17 cells. Neutralization of these cytokines led to substantial reduction of memory Th17 cells. Both IL-7 and IL-15 provided survival signals by activating STAT5 (Signal transducer and activator of transcription 5), and IL-15 provided additional proliferation signals by activating both STAT5 and Akt (Protein kinase B).
Topical neutralization of IL-7 or IL-15 in the eye effectively reduced memory Th17 cells at the inflammatory site and draining lymphoid tissues, while topical neutralization of IL-17 alone, the major pathogenic cytokine secreted by Th17 cells, did not diminish memory Th17 cells at the draining lymphoid tissues.
The results obtained during this study suggested that treatment to remove pathogenic memory Th17 cells via abolishing environmental IL-7 or IL-15 would be a novel strategy in the treatment of autoimmune diseases.
“We wanted to know the precise factors that maintain memory in Th17 cells so that we can better understand what is causing chronic autoimmune disorders,” said senior author Dr. Reza Dana, professor of ophthalmology at Harvard Medical School. “By selectively targeting the production and expression of IL-7 and IL-15, we may be able to prevent the development of chronic autoimmune disorders.”
“In the case of dry eye disease, many of the treatments are showing limited efficacy in patients that do not have a highly inflamed eye,” said Dr. Dana. “Targeting the chronic, immune nature of autoimmune diseases may be a better strategy for controlling these conditions.”
Th17 (T helper 17) cells are principal mediators of many autoimmune conditions. Persistent memory Th17 cells have been revealed as crucial in mediating the chronicity of various autoimmune disorders; however, the underlying mechanisms maintaining memory Th17 cells have remained elusive.
Investigators at Harvard Medical School used a mouse model of an ocular autoimmune disease to further elucidate the mechanism controlling the behavior of Th17 cells,
The investigators reported in the November 26, 2016, online edition of the Journal of Autoimmunity that both IL-7 and IL-15 were critical for maintaining pathogenic memory Th17 cells. Neutralization of these cytokines led to substantial reduction of memory Th17 cells. Both IL-7 and IL-15 provided survival signals by activating STAT5 (Signal transducer and activator of transcription 5), and IL-15 provided additional proliferation signals by activating both STAT5 and Akt (Protein kinase B).
Topical neutralization of IL-7 or IL-15 in the eye effectively reduced memory Th17 cells at the inflammatory site and draining lymphoid tissues, while topical neutralization of IL-17 alone, the major pathogenic cytokine secreted by Th17 cells, did not diminish memory Th17 cells at the draining lymphoid tissues.
The results obtained during this study suggested that treatment to remove pathogenic memory Th17 cells via abolishing environmental IL-7 or IL-15 would be a novel strategy in the treatment of autoimmune diseases.
“We wanted to know the precise factors that maintain memory in Th17 cells so that we can better understand what is causing chronic autoimmune disorders,” said senior author Dr. Reza Dana, professor of ophthalmology at Harvard Medical School. “By selectively targeting the production and expression of IL-7 and IL-15, we may be able to prevent the development of chronic autoimmune disorders.”
“In the case of dry eye disease, many of the treatments are showing limited efficacy in patients that do not have a highly inflamed eye,” said Dr. Dana. “Targeting the chronic, immune nature of autoimmune diseases may be a better strategy for controlling these conditions.”
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples